College of Psychiatric and Neurologic Pharmacists

Saturday, April 17, 2010

7:30 a.m.-4:30 p.m.

Board of Pharmaceutical Specialties (BPS) Item Writing Workshop*

12:00-2:30 p.m.

CPNP Board of Directors Meeting*

2:00-6:00 p.m.

Registration for Board & Committees*

3:00-4:00 p.m.

CPNP Committee Chair/Vice Chair/Board Liaison Meeting*

4:30-6:30 p.m.

2010-2011 Committee Meetings*

*Not ACPE and CME Approved

+Recertification Approved

Sunday, April 18, 2010

7:00 a.m.-5:30 p.m.

Registration*

8:00-11:00 a.m.

Pre-Meeting Workshop:  Managing Diabetes in Patients with Psychiatric Illness
Stuart Haines; Joshana Goga
ACPE #0284-0000-10-001-L01-P (Application)

Learning Objectives

1. State key recommendations from the American Diabetes Association guidelines for the management of diabetes.
2. Describe current pharmacological approaches for the management of diabetes in a patient with a psychiatric diagnosis.
3. Develop a monitoring plan for a patient with diabetes to determine if glycemic goals are being met.
4. Identify strategies to achieve optimal patient outcomes and to prevent diabetes-related complications.
5. Demonstrate how to teach a patient how and when to self-monitor blood glucose.

1:30-1:45 p.m.

Opening Remarks*
2009-2010 CPNP President, Ann Richards
2009-2010 CPNP Recertification Chair, Rex Lott

1:45-2:45 p.m.

In a World of Their Own:  Diagnosis and Treatment of Autism+
Kimberly A. Stigler
ACPE #0284-0000-10-002-L01-P; #0284-0000-10-002-H01-P (Knowledge)

Learning Objectives

1. Distinguish between the signs and symptoms of autism and the other pervasive developmental disorders.
2. Compare evidence and non-evidence based pharmacologic intervention for autism, with a focus on target symptoms, efficacy, and safety.
3. Formulate a comprehensive treatment plan for a patient with autism disorder, including both pharmacological and non-pharmacological treatment.

3:00-5:15 p.m.

New Drugs and Formulations in Psychiatry:  Critical Analysis in Formulary Decision-Making+
Patrick Bryant; Cindy Mascarenas
ACPE #0284-0000-10-003-L01-P; #0284-0000-10-003-H01-P (Knowledge)

Learning Objectives

1. Identify steps for formulary addition of medications in different practice settings.
2. Compare common reasons for medications to be added or deleted from medication formularies.
3. Explain concerns associated with the decision making process of approving a medication onto a formulary when the medication is a specific isomer of or has a different delivery mechanism from an existing product.
4. Describe the basic principles in preparing and completing an evidence-based medicine review.
5. Explain the critical analysis 5-Step EBM Process and provide an example of its application in the formulary review process.
6. Discuss options for formulary decision-making when the desired quality or level of data does not exist.
    

5:30-7:00 p.m.

Scientific Poster Display-Session I*
Wine & Cheese Reception*
Posters Manned by Corresponding Author

*Not ACPE and CME Approved

+Recertification Approved

Monday, April 19, 2010

7:00 a.m.-6:00 p.m.

Registration*

6:45-7:45 a.m.

Attendee Breakfast and Welcome Breakfast for New Members and 1^st Time Attendees*

7:45-8:00 a.m.

Opening Remarks*

Program Chair Plaque Presentation*
2009-2010 CPNP President, Ann Richards
2009-2010 CPNP Program Chair, Joshana Goga

8:00-8:15 a.m.

Saklad Award Presentation*
Raymond C. Love

8:20-9:50 a.m.

Keynote Address-Inside the Suicidal Mind:  Life Saving Insights & Critical Therapeutic Strategies
Terry Wise
ACPE #0284-0000-10-004-L05-P (Knowledge)

Learning Objectives

1. Develop methods to re-establish trust following a patient’s suicide attempt.
2. Discuss “contracting for safety” and strategies to facilitate disclosure of suicidal ideation.
3. Use strategies to navigate recurrent suicidality.
4. Recognize “turning points” during recovery from a suicide attempt survivor’s perspective
5. Identify and address underlying experiences that contribute to suicidal urges.
6. Demonstrate how you would provide support to those in the aftermath of a completed or attempted suicide.

10:15-11:15 a.m.

Life After Star*D:  Lessons Learned and the Next Steps for Managing Depression
Ben Kurian
ACPE #0284-0000-10-005-L01-P (Knowledge)

Learning Objectives

Session Description: 
This session will provide an in-depth discussion on the lessons learned from the NIMH sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial and an overview of future directions. The session will also provide a discussion on why Practical Clinical Trials involving “real world” patients, such as STAR*D, are more likely to provide results that can be immediately utilized in clinical practice. The presentation will also present a model for possible biomarker studies in depression.

Educational Goal:
The goal of this session is to provide attendees with an overview of the currently available literature for major depressive disorder (MDD), with a particular emphasis on the STAR*D trial and lessons learned. In addition, attendees will be able to discuss the potential role of biomarkers in the selecting treatments for MDD.

Learning Objectives:

1. Identify the gap between efficacy trials and “real world” patients and the implications for clinical practice.
2. Review the lessons learned from STAR*D, and how they translate to clinical practice. 
3. Discuss how clinical trials influence clinical practice. 
4. Discuss the future direction of depression comparative effectiveness trials.

11:15 a.m.-1:15 p.m.

Industry Supported Symposium #1
From Rating Scales to Reality:  Translating Clinical Trial Data into Meaningful Clinical Outcomes in Schizophrenia-Supported by Lilly

Concurrent Track I: Depression

1:30-2:30 p.m.

Strategies for the Management of Treatment-Resistant Depression
Scott Aaronson
ACPE #0284-0000-10-007-L01-P (Knowledge)

Learning Objectives

1. Recognize the definitions and clinical challenges of managing treatment-resistant depression
2. Compare the pharmacologic agents that have shown to be efficacious in treatment-resistant depression
3. Outline the recent advances in non-pharmacologic strategies to manage treatment-resistant depression

2:45-3:45p.m.

The Role of Folate in Depression and Dementia:  The Burden of Vitamin Deficiency
Teodoro Bottiglieri
ACPE #0284-0000-10-010-L04-P (Knowledge)

Learning Objectives

1. Describe the metabolism of folate and what factors impact folate activity.
2. Identify tests that diagnose folate deficiency in humans.
3. Recognize the biochemical mechanisms of folate deficiency that can lead to depression and dementia.
4. Develop a pharmacotherapy plan and monitoring parameters for a patient with folate deficiency.

Concurrent Track II: Research/Networking

1:30-3:45 p.m.

Award Finalist Platform Presentations
ACPE #0284-0000-10-006-L01-P (Knowledge)
PharmD/Resident Award
1:30-1:50 p.m.: Hannah Chandler, Antidepressant Use in Depressed Kentucky Medicaid Youths
1:50-2:10 p.m.: Parris Pope, The Effects of Second-Generation Antipsychotics on Executive Function: a Literature Review and Meta-analysis
Innovative Practices Award
2:10-2:30 p.m.:  Brandy Singer, Pharmacist Administration of Long-Acting Antipsychotic Injections in a Community Setting
2:45-3:05 p.m.: Judith Hyatt, Pharmacist-Directed PTSD Medication Management Clinic at the VAWNY Healthcare System
Therapeutic Case Report Award
3:05-3:25 p.m.: Catherine Millares, Duloxetine-Induced Seizure Breakthrough with Positive Dechallenge and Rechallenge
3:25-3:45 p.m.: Benjamin Chavez, Leuprolide-Induced Mania with Psychotic Symptoms in a Male Patient with No Prior Psychiatric History

Learning Objectives

 

Concurrent Track III: Evidence-Based Practice/BCPP Recertication Programming

1:30-2:30 p.m.

Long-Term Effect of In-Utero Exposure to Psychotropic Medications+
Alicia Forinash
ACPE #0284-0000-10-008-L05-P; #0284-0000-10-008-H05-P (Knowledge)

Learning Objectives

1. Contrast common fetal malformation types for antidepressant, antipsychotic and traditional mood stabilizing medications.
2. Compare cognitive outcomes of children after prenatal exposure to antidepressant, antipsychotic and traditional mood stabilizing medications.
3. Explain the role and limitations of the National Register of Antipsychotic Medications in Pregnancy (NRAMP) and the North American Pregnancy Registry in the pharmacovigilance of in utero exposure to psychotropic drugs.
4. Identify pharmacists’ role in patient education regarding risk versus benefit of psychotropic drugs during pregnancy.

2:45-3:45 p.m.

Improving Outcomes in Patients with Traumatic Brain Injury+
Amy Bowles; Douglas Cooper
ACPE #0284-0000-10-003-L04-P; #0284-0000-10-011-H04-P (Knowledge)

Learning Objectives

1. Understand the context of combat-related TBI and the scope of the problem
2. Recognize classification of severity of injury
3. To understand prognostic factors and their impact on clinical outcomes
4. To review evidence-based pharmacological interventions after brain injury
5. To understand the effects of psychiatric symptoms on clinical presentation after mild traumatic brain injury

3:50-5:30 p.m.

Industry Supported Symposium #2
Long-Acting Injectables: A to Z-Supported by Lilly

5:45-6:45 p.m.

Special Interest Roundtables*
Administrators/Directors/Managers:  Steve Burghart, Facilitator
Canadian Pharmacists:  Holly Reeves, Facilitator
New Practitioners/Residents/Fellows:  Troy Moore, Facilitator
State Hospital Pharmacists:  Rachael Fantz Hancock, Facilitator
Veterans Affairs Pharmacists:  Jonathan Lacro, Facilitator

6:45-8:15 p.m.

Outgoing President’s Reception/Poster*
Session II Manned*
Posters Manned by Corresponding Author

*Not ACPE and CME Approved

+Recertification Approved

Tuesday, April 20, 2010

8:00 a.m.-5:00 p.m.

Registration*

9:00-11:00 a.m.

Efficacy vs. Adverse Effects:  Which Trumps?  Point-Counterpoint
Peter Buckley and Henry Nasrallah
ACPE #0284-0000-10-012-L01-P (Knowledge)

Learning Objectives

Session Description
This session will provide a thorough and engaging discussion about the relative efficacy and tolerability profiles of the typical antipsychotic and the atypical antipsychotics, in the context of individualizing treatments for patients with schizophrenia.

The contemporary treatment of schizophrenia has (paradoxically) become increasingly complex with the greater availability and choice among antipsychotic medications. At the same time, there is still substantial debate and contention, fuelled by recent large pragmatic trials in schizophrenia, that the balance of efficacy and tolerability considerations remains complex and as yet inadequately predicted for the individual therapeutic context. Incorporating evidence from various sources on efficacy, safety, and tolerability, to develop effective and individualized strategies improving therapeutic outcomes are key considerations. To address these aspects, we will engage in a lively debate-designed to also engage our audience. This format for this interactive session will be designed to provide a review of the available literature followed by a debate format between two well known clinical researchers regarding efficacy vs. tolerability of antipsychotics in the treatment of schizophrenia.

Educational Goal
The goal of this session is to provide the attendee with the background needed to adequately weigh the risks and benefits associated with antipsychotic medications. As a result, he or she will be able to make evidence-based, balanced clinical decisions regarding antipsychotic regimens during the acute and maintenance treatment phases for patients with schizophrenia.

Learning Objectives

1. Identify the available literature regarding and differentiate the relative efficacy of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment.
2. Identify the available literature regarding and differentiate the relative tolerability profiles of typical and atypical antipsychotics used in patients with schizophrenia during the acute and maintenance phases of treatment (considering morbidity and mortality, cost, and patient preference).
3. Compare and contrast the risk-benefit ratio of typical and atypical antipsychotics in the treatment of schizophrenia.
4. Discuss the importance of efficacy versus tolerability in the clinical decision making process for the individualized treatment of schizophrenia during the acute and maintenance phases.

11:30-11:45 a.m.

Research Award Winner Announcements*
Vicki Ellingrod, Jeff Bishop, Poster and Award Chairs

12:00-2:00 p.m.

Industry Supported Symposium #3
When Antidepressants Fall Short:  Augmentation Strategies in Major Depressive Disorder-Supported by AstraZeneca

Concurrent Track I:  Special Populations

2:15-3:15 p.m.

Management of Psychiatric Illness in HIV Patients:  A Major Treatment Dilemma
Kathy Graham
ACPE #0284-0000-10-013-L02-P (Knowledge)

Learning Objectives

1. Outline pathophysiology of HIV and how it relates to the development of psychiatric illnesses (e.g., depression, psychosis).
2. Indicate the treatment challenges involved in HIV patients with psychiatric comorbidities.
3. Identify the most common drug-drug interactions (DDIs) with antiretrovirals and psychotropics.
4. Identify most appropriate treatment and management of DDIs in HIV patients with psychiatric illnesses.

Concurrent Track II:  Issues of the Day

2:15-3:15 p.m.

Genetic Epidemiology of Early-Onset Depression and Alcohol Use Disorders
Doug Williamson
ACPE #0284-0000-10-014-L01-P (Knowledge)

Learning Objectives

1. Evaluate the role of genetics and environment on the development of alcohol use disorders in adolescents
2. Compare the genetic, environmental and neural risk factors for depression and alcohol use disorders in children and adolescents
3. Discuss implications for treatment of alcohol use disorders in adolescents

3:30-4:30 p.m.

Clinical Pearls
ACPE #284-000-10-015-L01-P
Sarah Popish, "Rhoid Rage": A Self-Defense Plea in a Criminal Trial
Tara Purvis, What One Case of Severe EPS Can Teach You
Jennifer Nelson, Making a Good Connection: the Impact on Patient Care
Paul Price, Impacting Lives in Forensic Pharmacy: The Literature is Your Friend

Learning Objectives

1. Assess if anabolic steroid-induced mania is of sufficient severity to justify a self-defense plea in a murder trial.
2. Establish the continued need for training in recognizing and treating drug-induced movement disorders by highlighting a case of delayed diagnoses and treatment of EPS.
3. Analyze the key factors to developing good rapport with psychiatric patients.
4. Illustrate how a psychiatric pharmacy expert uses the literature to aid in the outcome of a legal case involving a psychotropic medication.

4:45-5:45

Current Issue Roundtables*
Conceptualizing Clinical Activities as Research
Facilitators: Tawny Smith, Nick Patel
Payment for Pharmacist Services – How Do We Get There?
Facilitators: Carla Cobb, Ray Love

*Not ACPE or CME Approved

+Recertification Approved

Wednesday, April 21, 2010

6:45-7:45 a.m.

CPNP Walks for NAMI*

8:30 a.m.-1:00 p.m.

Registration*

8:30-10:00 a.m.

Town Hall Meeting*

10:30-11:30 a.m.

Treatment of Cognitive Impairment in Schizophrenia
Dawn Velligan
#0284-0000-10-016-L01-P (Knowledge)

Learning Objectives

1. Discuss characteristics of patients most vulnerable to cognitive change.
2. Define improvement in cognition with pharmacological treatment.
3. Examine the impact of atypical antipsychotics on cognitive impairment.
4. Analyze literature on other treatment options for cognitive impairment.
5. Compare treatment options and formulate a treatment algorithm. 

11:30 a.m.-12:30 p.m. 

Strategies to Develop Disease Modifying Drugs:  Focus on Alzheimer’s and Surrogate Endpoints
Larry Ereshefsky
ACPE #0284-0000-10-017-L01-P (Knowledge)

Learning Objectives

1. Analyze the current state of the art for disease modifying drugs.
2. Explain research design methodology with a focus on Alzheimer’s disease.
3. Describe leading biosurrogate markers in the area of Alzheimer’s disease.
4. Analyze case illustrations for early drug development as targets for the therapeutics of Alzheimer’s Disease.

*Not ACPE or CME Approved

+Recertification Approved